Included patients (n = 433) | Excluded patients (n = 70) | p-value* | |
---|---|---|---|
Mean age in years (SD) | 66.3 (9.5) | 69.4 (9.9) | 0.01† |
Male | 61.2% | 68.6% | 0.24 |
Mean BMI (SD)* | 26.3 (5.2) | 26.0 (3.8) | 0.55 |
Comorbidities at time of enrollment into registry | |||
Hypertension | 41.3% | 45.7% | 0.81 |
Diabetes mellitus with end-organ damage | 0.7% | 2.9% | 0.27 |
Diabetes mellitus without end-organ damage | 14.6% | 18.6% | 0.50 |
Thyroid disease | 9.0% | 4.3% | 0.35 |
Coronary heart disease | 8.3% | 8.6% | 1.00 |
Tumor other than colorectal or lymphoma or leukemia | 7.9% | 7.1% | 1.00 |
Chronic gastric or bowel disease | 6.7% | 1.4% | 0.18 |
Adiposity | 6.5% | 2.9% | 0.44 |
Chronic pulmonary disease | 5.8% | 4.3% | 0.90 |
Anemia | 4.4% | 4.3% | 1.00 |
Heart failure | 4.2% | 7.1% | 0.44 |
Kidney disease | 3.5% | 8.5% | 0.15 |
Urogenital disease | 3.2% | 5.7% | 0.07 |
Cerebrovascular disease | 2.5% | 1.4% | 1.00 |
Myocardial infarction | 2.5% | 0.0% | 0.47 |
Peripheral artery occlusive disease | 2.1% | 1.4% | 1.00 |
Mild liver disease | 1.4% | 0.0% | 1.00 |
Moderate or severe liver disease | 0.7% | 0.0% | 1.00 |
Polyneuropathy | 1.9% | 1.4% | 1.00 |
Peptic ulcer disease | 0.5% | 0.0% | 1.00 |
Connective tissue disease | 0.5% | 0.0% | 1.00 |
Metastatic solid tumor other than colorectal | 0.5% | 0.0% | 1.00 |
Hemiplegia | 0.2% | 0.0% | 1.00 |
AIDS | 0.2% | 0.0% | 1.00 |
Myocardial insufficiency | 0.0% | 0.0% | 1.00 |
Dementia | 0.0% | 1.4% | 0.16 |
Localization of primary tumor | 0.82 | ||
Colon | 56.4% | 58.6% | – |
Rectum | 43.4% | 41.4% | – |
Inoperable primary tumor | 19.9% | 24.3% | 0.63 |
Tumor stage (UICC) at primary diagnosis | 0.82 | ||
I | 3.7% | 4.3% | – |
II | 7.2% | 5.7% | – |
III | 13.9% | 11.4% | – |
IV | 66.5% | 72.9% | – |
Progression prior to questioning | 0.27 | ||
0 | 75.3% | 75.7% | – |
1 | 16.6% | 12.9% | – |
2 or more | 4.4% | 7.1% | – |
Metastases | |||
Liver | 61.4% | 58.6% | 0.79 |
Lung | 23.8% | 21.4% | 0.83 |
Peritoneal | 14.6% | 20.0% | 0.49 |
Bone | 3.0% | 2.9% | 0.93 |
Number of metastatic localizations prior to questioning | < 0.01† | ||
0 | 10.9% | 7.1% | – |
1 | 51.2% | 55.7% | – |
2 | 24.9% | 27.1% | – |
3 or more | 7.6% | 5.7% | – |
Treatment line at time of questioning | 0.93 | ||
First-line palliative | 55.2% | 60.0% | – |
Break after first-line | 23.3% | 20.0% | – |
Second-line palliative or break after second-line | 15.5% | 14.3% | – |
Third-line palliative or later | 5.1% | 5.7% | – |
Most current chemotherapy at time of questioning | < 0.01† | ||
Irinotecan-based | 44.8% | 44.3% | – |
Oxaliplatin-based | 37.4% | 34.3% | – |
Fluoropyrimidine monotherapy | 10.4% | 15.7% | – |
Irinotecan plus oxaliplatin | 4.9% | 2.9% | – |
Additional antibody treatment | 0.68 | ||
None | 22.6% | 28.6% | – |
VEGF | 49.7% | 42.9% | – |
EGFR | 26.1% | 27.1% | – |
RAS mutation status | 0.74 | ||
Wild-type | 38.1% | 42.9% | – |
Mutation | 40.9% | 40.0% | – |